Document and Entity Information
Document and Entity Information | Jan. 24, 2023 |
Cover [Abstract] | |
Security Exchange Name | NASDAQ |
Amendment Flag | true |
Entity Central Index Key | 0001369568 |
Document Type | 8-K/A |
Document Period End Date | Jan. 24, 2023 |
Entity Registrant Name | CATALYST PHARMACEUTICALS, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-33057 |
Entity Tax Identification Number | 76-0837053 |
Entity Address, Address Line One | 355 Alhambra Circle |
Entity Address, Address Line Two | Suite 801 |
Entity Address, City or Town | Coral Gables |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33134 |
City Area Code | (305) |
Local Phone Number | 420-3200 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | CPRX |
Entity Emerging Growth Company | false |
Amendment Description | As previously disclosed in the Current Report on Form 8-K (the “Original Form 8-K”) filed by Catalyst Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission on January 30, 2023, on January 24, 2023 the Company acquired the U.S. rights to FYCOMPA® pursuant to an Asset Purchase Agreement (the “Purchase Agreement”) between the Company and Eisai Co. Ltd. (“Eisai”). This Current Report on Form 8-K/A (this “Amendment No. 1”) amends the Original Form 8-K to provide the financial statements and pro forma financial information required by Items 9.01(a) and 9.01(b) of Form 8-K that were previously omitted from the Original Form 8-K in reliance on Items 9.01(a)(3) and 9.01(b)(2) of Form 8-K. This Amendment No. 1 does not amend any other item in the Original Form 8-K, and all other information previously reported in or filed with the Original Form 8-K is hereby incorporated by reference into this Amendment No. 1. |